FibroBiologics, Inc. closed a private placement on September 15, 2026, raising approximately $0.5 million in gross proceeds from Hamid Khoja, Ph.D., the company's Chief Scientific Officer. The transaction involved the sale of 298,508 shares of common stock and accompanying warrants to purchase an equal number of shares at a combined price of $1.675 per unit, priced at-the-market under Nasdaq rules based on the September 14 closing bid. Each warrant carries an exercise price of $1.55 per share, is immediately exercisable, and expires five years from issuance. Shareholders also approved the issuance of up to 8,448,980 shares issuable upon the exercise of outstanding warrants under a June 2026 Securities Purchase Agreement and a November 2025 engagement letter with H.C. Wainwright & Co., LLC. The net proceeds will be used for general corporate purposes and working capital. FibroBiologics is a clinical-stage biotechnology company developing therapeutics for chronic diseases using fibroblast cells.
